The purpose of this study was to determine the effects of lutein supplement on serum cytokines, apoE and lipoprotein profiles in early atherosclerosis population. Methods: Early atherosclerosis patients (n = 65) were randomized to receive placebo (A＋P, n = 31) or 20 mg/d lutein (A＋L, n = 34) for 3 months. Results: Serum lutein increased significantly compared to baseline after lutein supplements in A+L group (p＜0.001). Lutein supplements resulted in a significant decrease in serum interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP- 
Introduction
Atherosclerosis is a pathologic status that underlies several important adverse vascular events, such as coronary disease, stroke, and peripheral arterial problems 1) . It has become the leading cause of cardiovascular morbidity and mortality in western societies, accounting for a fifth of deaths worldwide 2) . While the use of established medical therapies has reduced mortality from its complications, the adoption of a western lifestyle has led to a large increase in the prevalence of atherosclerosis throughout the world 3) ; therefore, the prevention of atherosclerosis remains a major public health challenge for both China and for western countries.
Atherosclerosis is an inflammatory disease 4) . Inflammation is a key regulatory process that links multiple risk factors for atherosclerosis and its complications 5) . Oxidized low density lipoprotein (oxLDL) induces endothelial dysfunction and recruits monocytes and lymphocytes, initiating the development of atherosclerosis lesions. Thereafter, cytokines and chemokines secreted by activated macrophages perpetuate and amplify inflammatory responses 6) . In atherosclerosis patients, the extent of inflammatory infiltrates and their strategic location within protective fibers is associated with plaque rupture and/or thrombosis 7) . Furthermore, circulating inflammatory biomarkers, especially C-reactive protein, have been found to be associated with outcomes of cardiovascular events, even in the absence of dyslipidaemia 8) . These findings support the inflammatory nature of atherosclerosis; therefore, there is a hypothesis that antioxidants such as carotenoids could be used as an inexpensive means of the prevention and possibly treatment of atherosclerosis and its complications.
Lutein, one of the most abundant carotenoids in mission of Peking University Health Science Department and all participants gave written informed consent.
Lutein Sources and Study Designs
Study substances were suspended in wild camellia oil and given in acid-soluble gelatin capsules. A placebo containing wild camellia oil (100%) was supplied in identical-looking capsules. All the subjects were instructed to consume one capsule per day immediately after lunch and to store the study substance at room temperature. All participants were encouraged to maintain their usual lifestyle and dietary habits. Compliance was assessed at the end of the study using pill counting, food records, and measurement of plasma lutein levels.
Anthropometric Parameters, Blood Pressure, and Blood Collection
Body weight and height were measured in the morning without shoes to calculate the body mass index (BMI) (kg/m 2 ). Blood pressure (BP) was measured in the left arm of seated patients after a 20-min rest. Study subjects were interviewed for smoking behavior and drug administration during their visits. After a 12-h fasting period, venous blood specimens were collected in EDTA-treated and plain tubes, centrifuged to produce plasma or serum, and stored at −70 ℃ until analysis.
Serum Lipid Profile, Fasting Glucose, ApoE and Cytokines Analysis
Serum total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), and glucose were measured within 2 days of collection by an autoanalyzer at Beijing Lawke Health Laboratory.
Apolipoprotein E (ApoE) and inflammatory cytokines, including monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), endothelin-1 (ET-1), interferon-γ (IFN-γ), and vascular cell adhesion molecule-1 (VCAM-1), were analyzed by a specific, commercially available ELISA kit (R&D Systems, Minneapolis, MN) with an ELISA reader at 450 nm, in accordance with the manufacturer's instructions. Sensitivity of the assay was 1.0 pg/mL for all the cytokines and the intra-and inter-assay coefficients of variation (CV) were 4.8% and 5.6%, respectively.
Plasma levels of lutein, zeaxanthin, β-carotene and lycopene were analyzed by high pressure liquid chromatography (HPLC) derived from the method described by Yeum et al. 17) . In brief, 500 μL serum, 500 μL internal standard (8-apo-β-carotenal) and 500 the human body 9) , is believed to play a protective role against atherosclerosis. In an epidemiological study, subjects with the highest serum lutein (0.42 μmol/L) had 80% less arterial wall thickening than those with the lowest quintile of serum lutein (0.15 μmol/L), while no such relationship was observed with serum beta-carotene 10) . Koh et al. also found that a high level of plasma lutein was associated with a decreased risk of acute myocardial infarction after adjustment for multiple risk factors for coronary heart disease in a Chinese population 11) . In animal experiments, a luteinenriched diet could inhibit cholesterol accumulation and decrease oxidized LDL and inflammatory cytokines in the aorta of Guinea pigs 12) . Other epidemiological studies, including the Atherosclerosis Risk in Communities (ARIC) study 13) and Health Professionals Follow-up Study 14) , also found possible beneficial effects of a lutein-rich diet.
Aim
Although experimental and epidemiological studies suggest the possible benefits of lutein against atherosclerosis, randomized control trials are scarce. In addition, atherosclerotic plaque development and progression are associated with inflammatory changes from early stages. Atherosclerosis plaque could be considered to be the result of interactions among modified lipoproteins, inflammatory cytokines and elevated cholesterol. In early atherosclerosis, serum inflammatory markers are sensitive predictors of lesion development. In our study, we examined the effects of lutein supplementation on serum lipoproteins, apoE and cytokines in early atherosclerosis patients and verified the possible benefits.
Participants and Methods

Subjects
The subjects of this study were from a follow-up visit of men and women in the The Beijing Atherosclerosis Study, a randomized, double-blind, placebocontrolled interventional trial that was designed to investigate the effects of lutein on in the prevention of atherosclerosis 15) . The study participants consisted of individuals with early atherosclerosis diagnosed by their carotid intima media thickness (IMT) 16) (as IMT ＞750 μm under 59 years old or carotid IMT ＞850 μm over 60 years old). Subjects of the present study were 65 patients after diagnosis. The patients were randomly assigned to receive 20 mg/d lutein (A＋L, n = 34) or a placebo control (A＋P, n = 31) for three months. The study was approved by the ethics com-carotenoids were quantified by reversed phase HPLC as described 15) .
Assessment of Dietary Intake
Dietary intake was assessed with a 24-h recall method for three days. Dietary energy and nutrient μL ethanol were pipetted into a 5 mL disposable test tube and vortexed for 1 min. The mixture was extracted with 700 μL hexane three times and the upper layer was collected and evaporated under nitrogen at 4 ℃. The residue was dissolved in solvent A (methanol : acetonitrile, 40:60 by vol.) and serum were tested by the independent-samples t test. Pearson's correlation coefficients were performed to exam the relationships between variables and are presented as r values. Two-sided p＜0.05 was considered significant. All analyses were conducted with SPSS 10.0 for Windows (SPSS Inc., Chicago, IL).
Results
Baseline Clinical Characters and Treatment Delivery
All enrolled subjects (n = 65) completed the three-month study. Compliance was high and no serious adverse reactions were noted. There were no crossovers during the 3-month follow-up period. At baseline, the study population age was 57.1±4.4; 41.5% male; 13.8% had diabetes mellitus; 36.9% had dyslipidemia. Participants in the two groups were well content were calculated using a computer program based on the standard tables of China Food Composition 18) .
Statistical Analysis
Continuous data are presented as the mean± standard deviation (SD) and categorical variables are expressed as percentages. All continuous variables were tested for normal distribution using the Shapiro-Wilk test. Baseline characteristics were compared using the χ 2 test for categorical variables and independent-samples t test for continuous variables. Serum cytokines and apoE are also presented as the median±interquar-tile range and tested by the Mann-Whitney U test. The three-month endpoints were assessed using the paired t test. Differences in the changes of variables from baseline to 3 months between the two groups 
Serum Lipid Profile and Blood Glucose
Atherosclerosis risk factors demonstrated a greater decrease in LDL-cholesterol among individuals in the A＋L group compared to baseline. Subjects in A＋L group had a statistically significant improvement in serum triglyceride compared to baseline (p = 0.001). The improvements of atherosclerosis risk factors between the two groups showed no significance ( Table 2) .
Relationship between Changes in Serum Lutein and LDL-Cholesterol
In all subjects, the change of lutein correlated negatively with changes in serum LDL-cholesterol (r =−0.340, p = 0.062). In particular, for subjects in A＋L group, the changes in serum lutein were significantly correlated with the change of LDL-cholesterol (r =−0.384, p = 0.043; Fig. 1 ).
Discussion
In this randomized, double-blind, placebo-controlled study, lutein supplementation had beneficial effects on biomarkers of inflammatory cytokines, as evidenced by decreased IL-6 and MCP-1 levels in A＋ L group. In addition, the change in serum lutein in A ＋L group was significantly negatively correlated with the change in LDL-cholesterol. These results suggested that the antioxidant effects of lutein may play a matched in terms of baseline demographics and performance variables. Baseline serum carotenoids, cytokines and apoE were also similar at baseline across the groups ( Table 1) .
Change of Serum Lutein Among Subjects
The lutein supplements resulted in a significant increase in serum lutein levels in the supplemented group compared to baseline (p＜0.001) but not in the placebo group at 3 months ( Table 2) 
Inflammatory Cytokines and ApoE
After the 3-month follow up, the changes of inflammatory cytokines varied in two groups ( Table 2) . In A ＋P group, there were no significant changes in cytokines compared to baseline. In contrast, in A＋L group, IL-6 and MCP-1 showed a significant decrease at 3 months (p＜0.05). For MCP-1, A＋L group demonstrated significant improvements compared with A ＋P group (p = 0.021). Subjects assigned to A＋L had great decreases in apoE than in A＋P group, but these were not significant (p＞0.05) ( Table 2) . A B sclerosis patients. From this result, lutein may play a beneficial role in preventing monocyte recruitment. As endothelial expression of MCP-1 is thought to be one of the biomarkers of endothelial dysfunction in early atherosclerotic lesions 26) , this result suggested the possible beneficial effects of lutein on the endothelium. Overall, the findings from this study suggested that lutein may have possible benefits on endothelial function.
The reduction of serum LDL-cholesterol, triglyceride level and the correlation between changes in lutein and serum LDL-cholesterol levels in this study suggest that lutein may play a role in serum lipid profile regulation. LDL could be modified into the oxidized form of LDL (oxLDL) by reactive oxygen species (ROS), which play a central proatherogenic role in the arterial wall 27) . Serum LDL cholesterol-related parameters could effectively predict the risk of cardiovascular diseases 28) , and therapies aimed at lowering serum LDL-cholesterol had significant effects on the progression of atherosclerosis 29, 30) . Although the mechanisms by which lutein exerts its biological functions in lipid regulation have not been well defined, evidence from an animal study suggested that xanthophyll carotenoids might lower serum LDL-cholesterol and triglyceride levels by increasing LDL uptake and fatty acid β-oxidation 31) . Yang et al. observed that the livers of mice fed astaxanthin, another xanthophyll carotenoid, had significantly higher greater mRNA levels of LDL receptor, 3-hydroxy-3methylgutaryl CoA reductase, and sterol regulatory element bind protein 2. They also found that mRNA abundance of several important enzymes in fatty acid β-oxidation, including carnitine palmitoyl transferase 1, acetylCoA carboxylase β and acyl-CoA oxidase, was significantly increased after astaxanthin supplementation. In humans, astaxanthin administration also showed a lipid-lowering effect 32) , consistent with the effect of lutein observed in this study. Because the structure of lutein is very similar to that of astaxanthin 33) , it is probable that lutein exerts its function through the same mechanisms. Furthermore, serum apolipoprotein E, a determiner of triglyceride-rich lipoprotein metabolism 34) , decreased after lutein supplementation in this study. In general, serum apoE could explain 20%-40% of variability in triglyceride levels in humans 34) , and high levels of serum apoE appear to cause hypertriglyceridemia by stimulating triglyceride production and impairing VLDL lipolysis 35) ; therefore, the reduction of serum triglyceride in this study may be also due to, at least in part, decreased serum apoE after lutein supplementation. ApoE was synthesized from several cell lines, including hepatocytes, role in the prevention of atherosclerosis progression, which was closely related with inflammatory cytokines and LDL. The reductions in inflammatory cytokines after lutein supplementation were consistent with the previous findings that multiple inflammatory cytokines were inhibited in the aorta of guinea pigs following feeding with a lutein-enriched diet 12) . More recently, Gao et al. also found that supplementation of xanthophylls (containing 40% lutein and 60% zeaxanthin) decreased proinflammatory and increased anti-inflammatory cytokines in hens and chicks 19) . In this study, lutein supplementation significantly increased serum lutein from baseline in the supplemented group compared to the placebo. This result confirms the compliance of the study subjects and the good response of participants to lutein supplementation.
Interleukin-6, a proinflammmatory cytokine produced in various tissues, was demonstrated to be associated with both atherosclerotic plaque development and plaque destabilization effects in the atherosclerosis pathway 20) . Recently, Boekholdt et al. pointed out that IL-6 and its receptor can active an alternative trans-signaling pathway, mainly in endothelial cells and smooth muscle cells, and have a causative role in determining the risk of coronary heart disease 21) . As IL-6 has a key role in mediating inflammatory cascades and is concomitant with atherosclerosis complications 22) , the favorable impact of lutein supplementation on the IL-6 level seen in this study supported its function in the system inflammatory pathway and in atherosclerosis prevention. The improvement of IL-6 was greater in A＋L group than in A＋P group, although there was no significance. These results suggested that lutein might exert its biological function by inhibiting oxidative stress and regulating the inflammatory pathway 23) , which were active in early atherosclerosis patients 4) . Macrophages, differentiated from monocytes recruited from circulating blood, are believed to play key roles in atherosclerosis lesion initiation and early progression 24) . Chemokine receptors on the surface of monocytes could interact with the chemokines secreted by activated endothelial cells and promote the directional migration of monocytes 25) . MCP-1, a potent monocyte attractant, was demonstrated to be the key molecular link between oxidized lipoprotein and macrophage recruitment to the vessel wall in early atherosclerosis 26) . In a mouse model of atherosclerosis, atherogenesis could be prevented or retarded by blocking chemokines or their receptors, which were related to monocyte entry 25) . In our study, lutein supplementation significantly decreased MCP-1 in early athero-macrophages, astrocytes and smooth muscle cells. Macrophages were found to be the cell type responsible for the production of apoE in various tissues in response to injury and repair 36) . For the early stage of atherosclerosis, recruitment of macrophages to injured vascular endothelial cells and their subsequent uptake of cholesterol were the major cellular events contributing to the development of atherosclerosis 37) . Macrophages would synthesize and secrete large quantities of apoE after taking up cholesterol 36) , which might be an important source of serum apoE in atherosclerosis patients. Evidence from vitro and vivo studies demonstrated that lutein could effectively suppress the inflammatory responses of macrophages 38) . Moreover, findings from our study and others suggested that lutein could inhibit the attraction of monocytes to the surface of injured vascular endothelial cells 10) . This suggested that lutein might lower serum apoE by suppressing inflammatory responses and inhibiting the recruitment of macrophages. More studies are needed to confirm these results.
Conclusion
In this study, there were more female than male subjects. Because age and gender are important factors determining endothelial function 39) , the gender imbalance and the age distribution in this study should be noted in the generation of the results. Despite these limitations, 3 months of 20 mg/d lutein supplementation increased serum lutein and decreased serum inflammatory cytokines and serum TG and LDL-cholesterol. In addition, changes in serum lutein correlated negatively with those of serum LDL-cholesterol. These results add to the growing literature on the potential protective effects of lutein in atherosclerosis through anti-inflammatory effects and preservation of endothelial function.
